LCK
ENSG00000182866
Target class
Kinase
Chromosome
1
Approved drugs
2
Clinical candidates (approved and in development)
7
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- LCK
- Gene name
- LCK proto-oncogene, Src family tyrosine kinase
- Gene symbol
- LCK
- Protein name
- Tyrosine-protein kinase Lck (EC 2.7.10.2) (Leukocyte C-terminal Src kinase) (LSK) (Lymphocyte cell-specific protein-tyrosine kinase) (Protein YT16) (Proto-oncogene Lck) (T cell-specific protein-tyrosine kinase) (p56-LCK)
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing|Src family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 29
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 101.95
- Tissue specificity (Gini)
- 0.804
- Tissue specificity (tau)
- 0.962
- KEGG gene identifiers
- hsa:3932
- R-HSA-114604
- R-HSA-1257604
- R-HSA-1433557
- R-HSA-1433559
- R-HSA-164944
- R-HSA-167590
- R-HSA-202424
- R-HSA-202427
- R-HSA-202430
- R-HSA-202433
- R-HSA-210990
- R-HSA-2219530
- R-HSA-2424491
- R-HSA-389356
- R-HSA-389357
- R-HSA-389359
- R-HSA-389513
- R-HSA-389948
- R-HSA-6811558
- R-HSA-9013407
- R-HSA-9020558
- R-HSA-9670439
- R-HSA-9706374
- End position
- 32286170
- Start position
- 32251244
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Lipid-anchor
- Cytoplasmic side . Cytoplasm, cytosol . Note=Present in lipid rafts in an inactive form. .
- Golgi apparatus
- PubMed 12218089
- PubMed 22034844
- Tissue specificity (tau)
- 0.961639
- Expression inequality (Gini)
- 0.803564
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 101.95
- Spleen
- 52.7
- Whole Blood
- 47.71
- Small Intestine - Terminal Ileum
- 20.15
- Lung
- 13.78
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes101.95
- Spleen52.7
- Whole Blood47.71
- Small Intestine - Terminal Ileum20.15
- Lung13.78
- Thyroid4.31
- Colon - Transverse4.31
- Fallopian Tube3.88
- Adipose - Visceral (Omentum)3.88
- Cervix - Endocervix3.8
- Prostate3.76
- Vagina3.56
- Kidney - Medulla3.47
- Stomach3.07
- Bladder2.95
- Cervix - Ectocervix2.84
- Esophagus - Mucosa2.6
- Adipose - Subcutaneous2.3
- Minor Salivary Gland2.28
- Uterus2.16
- Artery - Coronary2.09
- Breast - Mammary Tissue1.87
- Artery - Aorta1.72
- Liver1.61
- Nerve - Tibial1.51
And 29 more, listed on the interactive page.
- GO:0009410
- GO:0030168
- GO:0030217
- GO:0031295
- GO:0034116
- GO:0035556
- GO:0038094
- GO:0042110
- GO:0050852
- GO:0050870
- GO:0050900
- GO:0051132
- GO:0160162
- GO:1903039
- GO:2001244
- GO:0000242
- GO:0001772
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0045121
- GO:0070062
- GO:0001784
- GO:0004713
- GO:0004715
- GO:0004722
- GO:0005515
- GO:0016004
- GO:0019901
- GO:0019903
- GO:0042169
- GO:0042608
- GO:0042609
- GO:0042610
- GO:0042802
- GO:0043274
- GO:0043548
- GO:0051117
T cell activation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: T cell activation
Biological samples
- Immune
PubMed 23197038SCID-like immunodeficiency
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: SCID-like immunodeficiency
Biological samples
- Immune
PubMed 23197038T cell inhibition
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: T cell inhibition
Biological samples
- Immune
PubMed 23197038
Related records
Trials (1,163)
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- A Bioequivalence Study of Dasatinib Tablet
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
- A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
- A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
- A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.
- A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Drugs (16)
- Acalabrutinib
- Dasatinib
- Dasatinib anhydrous SRC inhibitor
- Dasatinib laurylsulfate SRC inhibitor
- ENMD-981693 SRC inhibitor
- Ibrutinib
- Ilorasertib SRC inhibitor
- JNJ-26483327 Tyrosine-protein kinase LCK inhibitor
- Nefextinib
- Pazopanib Tyrosine-protein kinase LCK inhibitor
- Pazopanib hydrochloride Tyrosine-protein kinase LCK inhibitor
- Pexidartinib
- Saracatinib
- TAK-020
- TG100-801 SRC inhibitor
- XL-228 SRC inhibitor